For degradation of PARP2, Olaparib was successfully conjugated to KB02 via a PEG linker and showed degradation of PARP2 in triple-negative breast cancer (TNBC) cell lines MDA-MB-231 both in vitro and in vivo [39]. The gene discussed is PARP2; the disease is triple-negative breast carcinoma.